Introduction
============

The vascular system plays a crucial role in organ homeostasis, being essential for organ and tissue construction, the supply of oxygen and nutrients, and mobilization of inflammatory cells to regions of injury^[@bib1],\ [@bib2])^. Current and novel therapeutic approaches aimed at improving vascular function provide real benefits with respect to reducing cerebrovascular disease^[@bib3])^. In addition, the vascular system can be considered the largest system in the body, given its length and area, and via its active secretion of bioactive molecules, plays a central role in vascular homeostasis^[@bib4]--[@bib6])^. Revealing the mechanisms underlying the functional integrity of the vascular system could lead to novel approaches to therapy and preventive medicine.

Strokes are associated closely with vascular homeostasis, and disruption of vascular function can also cause a stroke. A stroke is the clinical culmination of several complex processes and interacting pathways that involve various genetic and environmental factors^[@bib7])^. Genetic contributions to strokes may result from common variants with small effect sizes, rare variants with large effect sizes, or their combination^[@bib8])^. However, environmental risk factors are associated with the pathogenesis of stroke, and considerable evidence suggests that geneenvironment interactions are important^[@bib9])^.

Adrenomedullin (ADM) is a vasoactive peptide first identified in human pheochromocytoma^[@bib10])^. Although ADM is secreted by various organs and tissues, it is produced mainly by vascular endothelial cells and serves a number of physiological functions^[@bib11]--[@bib14])^. The ADM receptor is a seven transmembrane domain G protein-coupled receptor, called the calcitonin-receptor-like receptor (CLR)^[@bib15],\ [@bib16])^. The specificity of CLR for ADM is thought to be regulated by receptor activity-modifying proteins (RAMPs), which are membrane proteins having a single membrane-spanning domain. Analysis of genetically engineered knockout mice revealed that the ADM signal is indispensable for CLR and RAMP2 function^[@bib17]--[@bib20])^. By contrast, there have been few studies of the ADM receptor system in humans.

The present study aimed to analyze *RAMP2* and *CLR* single nucleotide polymorphisms (SNPs) and evaluate their association with stroke in the light of gene-environment interactions. This analysis was conducted as a cross-sectional study using a large-scale pooled analysis of the Japanese general population.

Methods
=======

Study Participants
------------------

In the present study, we evaluated participant data collected during the Japan Multi-Institutional Collaborative Cohort (J-MICC) Study from the baseline surveys using the cross-sectional data. That cohort study evaluated the general Japanese population in 12 research areas, using genetic and clinical data to detect and confirm gene-environment interactions related to lifestyle-associated diseases^[@bib21])^. The study participants were 35--69 years old, and were enrolled after responding to study announcements in their specific research areas, attending health check-up examinations that were commissioned by their local governments, visiting local health check-up centers, or visiting a cancer hospital. A total of 14,539 participants were selected. We analyzed the data while minimizing the number of deleted participants. Each parameter was separated in the analysis because of missing data.

The J-MICC study participants included citizens, health check examiners, and first-visit patients to a cancer hospital. All participants in this study gave written informed consent. The study protocol was approved by the Ethics Committees at Aichi Cancer Center, the Nagoya University Graduate School of Medicine, and other institutions participating in the J-MICC study. The present study was conducted according to the principles expressed in the World Medical Association Declaration of Helsinki.

Lifestyle and Blood Biochemistry Data
-------------------------------------

In the present study, we evaluated the lifestyle and medical information obtained through self-administered questionnaires (alcohol consumption status, smoking habits, and physical exercise). The body mass index (BMI) was calculated as weight (kg) divided by the square of height (m^2^). Obesity was defined as a BMI ≥ 25.0 kg/m^2^. Alcohol consumption of each type of beverage was determined by the average number of drinks per day, and then converted into the Japanese sake unit, 'gou' (180 ml), which is equivalent to 23 g of ethanol (0, 0.1--22.9, 23.0--45.9, or ≥ 46.0 g ethanol/day). Regular physical activity was defined as three times a week and lasting over 30 minutes. Anamnesis and medication history were also assessed using a questionnaire. Information on stroke (*n* = 248) and ischemic heart disease (*n* = 403) was available from the self-administered questionnaires. Hypertension was defined as a systolic/diastolic blood pressure ≥ 140/90 mm Hg and/or current use of medication for hypertension. Dyslipidemia was defined as non-high density lipoprotein-C (HDL-C) ≥ 170 mg dl^−1^ and/or HDL-C \< 40 mg dl^−1^ and/or current use of medication for dyslipidemia. Diabetes was defined as a glycated hemoglobin (HbA1c) level ≥ 6.5% and/or current use of medication for diabetes. The participants who have the absence of laboratory data and/or insufficient data were excluded in each analytic criterion.

In addition, blood chemistry data (serum levels of triglycerides, total cholesterol, HDL-C, non-HDL-C, creatinine, and HbA1c) and anthropometric data were obtained from health check-ups performed in the research areas. The estimated glomerular filtration rate (eGFR) was calculated using the following equation: eGFR (mL/min/1.73 m^2^) = 194 × creatinine^−1.094^ × age^−0.287^ (for men) and eGFR (mL/min/1.73 m^2^) = 194 × creatinine^−1.094^ × age^−0.287^ × 0.739 (for women)^[@bib22])^. Each blood sample was centrifuged and the plasma was separated and stored at −80°C until analysis. Laboratories in each research area analyzed the serum samples.

Genotyping and Quality Control Filtering
----------------------------------------

In the study, buffy coat fractions and DNA were prepared from blood samples and stored at −80°C at the central J-MICC study office. DNA was extracted from all buffy coat fractions using a BioRobot M48 Workstation (Qiagen Group, Tokyo, Japan) at the central study office. For the samples from two areas (Fukuoka and Kyushu-KOPS), DNA was extracted locally from samples of whole blood, using an automatic nucleic acid isolation system (NA-3000, Kurabo, Co., Ltd, Osaka, Japan). The 14,539 study participants from the 12 areas of the J-MICC study were genotyped at RIKEN Center for Integrative Medicine using a Human-OmniExpressExome-8 v1.2 BeadChip array (Illumina Inc., San Diego, CA, USA). Twenty-six samples with inconsistent sex information between the questionnaire and the estimate from the genotyping results were excluded. The identity-by-descent method implemented in the PLINK 1.9 software^[@bib23],\ [@bib24])^ identified 388 closely related pairs (pi-hat \> 0.1875) and one sample of each pair was excluded. Principal component analysis (PCA)^[@bib25],\ [@bib26])^ with the 1000 Genomes reference panel (phase 3)^[@bib27])^ detected 34 subjects whose estimated ancestries were outside of the Japanese population^[@bib28])^. These 34 samples were excluded. All the remaining 14,091 samples met a sample-wise genotype call rate criterion (≥ 0.99). SNPs with a genotype call rate \< 0.98 and/or a Hardy-Weinberg equilibrium exact test *P*-value \< 1 × 10^−6^ were removed, resulting in 873,254 autosomal variants. Among these, 298,644 variants with a low minor allele frequency (MAF) \< 0.01 were excluded. This quality control filtering resulted in 14,091 participants and 570,162 SNPs. After genotyping, data from four participants who withdrew from follow-up were excluded from further analysis, resulting in 14,087 participants were included in the analyses.

Genotype Imputation
-------------------

Genotype imputation was performed using SHA-PIT^[@bib29])^ and Minimac3^[@bib30])^ software based on the 1000 Genomes Project cosmopolitan reference panel (phase 3)^[@bib27])^. After the genotype imputation, variants with an R^2^ value \< 0.3 were excluded, resulting in 12,617,547 variants. We identified variants in the *RAMP2* and *CLR* loci, which identified two and 369 SNPs, respectively.

Statistical Analyses
--------------------

We compared the associations between various genotypes and stroke, after combining the heterozygous and minor homozygous alleles because of the small number of minor homozygotes. We selected SNPs from the *RAMP2* and *CLR* genes that exhibited a statistically significant association with stroke. Continuous variables are expressed as mean ± standard deviation (SD) and categorical data are expressed as sums and percentages. Inter-group comparisons were performed using Welch\'s *t*-tests for continuous variables, and the chi-square or Fisher\'s exact tests for categorical variables (sex, alcohol consumption, regular physical activity, smoking, stroke, obesity, ischemic heart disease, hypertension, dyslipidemia, and diabetes). The chisquare test was performed to examine the Hardy--Weinberg equilibrium for each locus studied. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using logistic regression analyses, in which stroke was defined as the dependent variable, and age, sex, research area, alcohol intake, current smoking, regular physical activity, obesity, hypertension, diabetes, dyslipidemia, and ischemic heart disease, were included as independent variables. The haplotype frequency and linkage disequilibrium of the SNPs were estimated using Haploview^[@bib31])^. All statistical tests were two-tailed, and differences with a *p*-value \< 0.05 were considered statistically significant. SPSS software (version 18.0, SPSS, Japan, Inc.) was used for all statistical analyses.

Results
=======

Among these 14,087 participants, the mean age of the included 6337 men was 55.4 years, compared to 54.3 years for the 7750 women.

We identified two and 369 SNPs among the genetic variants of *RAMP2* and *CLR*, respectively (**[Supplementary Table 1](#T5){ref-type="table"}**, Chromosomal locations were described based on hg19/GRCh37 coordinates). **[Supplementary Fig. 1](#F1){ref-type="fig"}** shows the linkage disequilibrium analyses of 13 *CLR* SNPs associated with stroke identified using the chi-square test. The position of the studied SNPs in *CLR* is shown. Pair-wise SNP R-squared D\' linkage values (multiplied by 100) are also shown. We then selected five SNPs from among the *CLR* variants (rs77035639, rs3815524, rs75380157, rs574603859, and rs147565266) to avoid similar haplotypes. Similarly, *RAMP2* SNP (rs753152), which is associated with stroke, was selected for analysis. The distributions of genotypes and alleles of the evaluated SNPs are summarized in **[Supplementary Table 2](#T6){ref-type="table"}. [Supplementary Fig. 2](#F2){ref-type="fig"}** shows exons (shown as boxes) 1--4 for *RAMP2*, and exons 1--15 for *CLR*. For analysis, we compared the associations between genotypes and stroke, after combining the heterozygous and minor homozygous alleles because of the small number of minor homozygotes alleles.

###### Genetic variants of the *RAMP2* and *CLR* loci.

  Gene      chromosome   Position                                                                            
  --------- ------------ ----------- ----------- ----------- ----------- ----------- ----------- ----------- -----------
  *RAMP2*   17           40913366    188216783   188225844   188236012   188252411   188269685   188287434   188298742
                         40913505    188216807   188225970   188236025   188252561   188269709   188287456   188298787
  *CLR*     2            188206953   188217247   188226414   188236053   188252608   188270337   188288165   188300228
                         188207245   188217379   188226520   188236279   188253796   188270560   188288259   188300873
                         188207585   188217500   188226900   188236354   188253902   188270687   188288266   188301149
                         188207611   188217501   188227008   188236378   188254046   188270864   188288315   188301544
                         188208012   188217706   188227300   188236458   188254173   188270914   188289056   188302053
                         188208120   188217738   188227302   188236819   188254581   188270925   188289079   188302587
                         188208130   188218342   188227302   188237045   188255091   188271085   188289172   188302634
                         188208290   188218458   188227613   188237868   188255237   188271819   188289174   188302770
                         188208736   188218683   188227754   188238101   188255432   188272092   188289448   188303700
                         188209158   188218937   188227921   188238103   188255549   188272460   188289795   188303845
                         188209159   188218946   188228516   188238334   188255912   188272951   188289849   188303979
                         188209179   188219052   188228911   188239574   188256158   188273829   188289964   188304095
                         188209709   188219186   188229007   188239647   188256237   188275146   188289971   188304213
                         188210214   188219325   188229335   188239809   188256685   188275930   188290419   188304446
                         188210256   188219447   188229622   188240559   188256910   188275982   188290490   188304891
                         188210257   188219468   188229739   188241519   188257985   188276272   188290717   188305046
                         188210415   188219975   188229820   188241522   188258904   188276515   188290969   188305110
                         188210586   188220301   188230146   188241953   188259620   188276584   188290969   188305797
                         188210673   188220317   188230333   188242861   188260401   188276906   188291105   188306215
                         188210960   188220384   188230588   188243363   188260747   188276987   188291382   188306229
                         188211005   188220446   188230692   188243503   188260912   188277123   188291723   188306543
                         188211112   188220865   188230976   188243620   188260913   188277455   188291869   188306768
                         188211296   188221302   188231072   188243633   188260921   188277682   188292242   188306985
                         188211443   188221350   188231216   188243658   188261266   188278035   188292458   188307038
                         188211568   188221547   188231433   188243684   188261890   188278203   188293391   188307334
                         188211568   188221648   188231645   188243940   188261922   188278226   188293438   188307429
                         188211610   188221793   188231887   188244430   188262362   188278525   188293545   188307608
                         188211789   188221911   188232223   188245890   188262468   188278822   188293614   188307747
                         188212371   188221943   188232805   188246023   188263003   188279122   188293635   188307962
                         188212423   188222351   188233502   188247648   188263325   188279606   188293921   188308056
                         188213235   188222428   188233524   188247843   188264246   188280382   188294598   188308240
                         188213336   188222469   188233714   188248440   188264602   188280870   188294980   188308604
                         188213538   188222560   188234194   188248594   188264833   188280896   188295534   188308640
                         188213819   188222561   188234520   188248663   188265242   188282330   188295611   188308853
                         188214239   188222581   188234678   188248727   188265543   188282703   188296132   188309875
                         188214694   188222928   188234844   188249420   188266531   188283002   188296488   188310118
                         188214823   188222946   188234928   188250234   188266951   188283061   188297133   188310305
                         188214924   188223256   188235033   188250476   188267147   188283123   188297160   188311515
                         188215045   188223889   188235100   188250718   188267147   188284000   188297214   188311900
                         188215156   188224057   188235162   188250860   188267193   188284127   188297348   188311992
                         188215209   188224322   188235258   188251427   188267470   188284824   188297349   
                         188215241   188224457   188235340   188251432   188268001   188285455   188297388   
                         188215292   188224928   188235611   188251535   188268541   188285710   188298159   
                         188215299   188225030   188235956   188251702   188268931   188286217   188298197   
                         188216078   188225240   188236000   188251972   188269235   188286516   188298341   

![The linkage disequilibrium analyses of 13 *CLR* (calcitonin-receptor-like receptor) SNPs associated with stroke.\
The haplotype structure and the position of the studied single nucleotide polymorphisms in the *CLR* gene exhibited a statistically significant association with stroke.](jat-24-1267-g001){#F1}

###### Allele and genotype frequencies of the *RAMP2* and *CLR* genes in the participants

  SNP                 Allele frequency   Genotype frequency   n       *P* for Hardy-Weinberg equilibrium
  ------------------- ------------------ -------------------- ------- ------------------------------------
  rs753152 (T/G)                                                      
      TT              T = 0.965          T/T = 0.933          13137   
      TG                                 T/G = 0.065          921     0.003
      GG              G = 0.035          G/G = 0.002          29      
  rs77035639 (A/G)                                                    
      AA              A = 0.983          A/A = 0.965          13604   
      AG                                 A/G = 0.034          476     0.177
      GG              G = 0.017          G/G = 0.001          7       
  rs3815524 (G/C)                                                     
      GG              G = 0.940          G/G = 0.885          12464   
      GC                                 G/C = 0.110          1552    0.003
      CC              C = 0.060          C/C = 0.005          71      
  rs75380157 (A/T)                                                    
      AA              A = 0.959          A/A = 0.921          12978   
      AT                                 A/T = 0.076          1073    0.006
      TT              T = 0.041          T/T = 0.003          36      
  rs574603859 (A/T)                                                   
      AA              A = 0.975          A/A = 0.952          13405   
      AT                                 A/T = 0.047          664     0.001
      TT              T = 0.025          T/T = 0.001          18      
  rs147565266 (T/A)                                                   
      TT              T = 0.998          T/T = 0.996          14024   
      TA                                 T/A = 0.004          63      0.790
      AA              A = 0.002          A/A = 0.000          0       

![Organization of the *RAMP2* (receptor activity-modifying protein 2) and *CLR* (calcitonin-receptor-like receptor) genes and locations of the SNPs used in the present study. Closed boxes indicate exons and lines represent introns.](jat-24-1267-g002){#F2}

**[Table 1](#T1){ref-type="table"}** shows the distribution of stroke for each SNP. The major homozygotes had significantly higher incidences of stroke compared with the heterozygotes and minor homozygotes, except for rs574603859. SNP rs574603859 showed an inverse ratio between major homozygotes and the other genotypes. **[Table 2](#T2){ref-type="table"}** summarizes the baseline characteristics of the participants divided into two groups, classified by major homozygous alleles versus heterozygous and minor homozygous alleles. None of the SNPs showed a constant tendency for these characteristics. **[Table 3](#T3){ref-type="table"}** shows the distribution of obesity, ischemic heart disease, hypertension, dyslipidemia, and diabetes for each SNP. SNP rs574603859 was associated with a higher incidence of obesity in the heterozygotes and minor homozygotes. SNP rs753152 was associated with a higher incidence of diabetes in the heterozygotes and minor homozygotes. The other four SNPs showed no significant association with these diseases.

###### Genotype and allele distributions in stroke.

  SNPs Chromosome: position                          Genotype      *p* value    
  ----------------------------------- -------------- ------------- ------------ -----------
  rs753152 (T/G) chr17: 40913505      control (n)    12139         881          **0.003**
  (%)                                 93.2%          6.8%                       
  Stroke (n)                          219            29                         
  (%)                                 88.30%         11.7%                      
                                                                                
  rs77035639 (A/G) chr2: 188220301    control (n)    12579         441          **0.020**
  (%)                                 96.6%          3.4%                       
  Stroke (n)                          232            16                         
  (%)                                 93.5%          6.5%                       
                                                                                
  rs3815524 (G/C) chr2: 188224322     control (n)    11519         1501         **0.041**
  (%)                                 88.5%          11.5%                      
  Stroke (n)                          209            39                         
  (%)                                 84.3%          15.7%                      
  rs75380157 (A/T) chr2: 188271085    control (n)    12005         1015         **0.002**
  (%)                                 92.2%          7.8%                       
  Stroke (n)                          215            33                         
  (%)                                 86.7%          13.3%                      
                                                                                
  rs574603859 (A/T) chr2: 188301544   control (n)    12375         645          **0.003**
  (%)                                 95.0%          5.0%                       
  Stroke (n)                          245            3                          
  (%)                                 98.8%          1.2%                       
                                                                                
  rs147565266 (T/A) chr2: 188311515   control (n)    12967         53           **0.022**
  (%)                                 99.6%          0.4%                       
  Stroke (n)                          244            4                          
  (%)                                 98.4%          1.6%                       

Homo, homozygote; Hetero, heterozygote.

###### Characteristics of study participants for each single nucleotide polymorphism (SNP).

  Genotype                          rs753152   *p* value                         
  --------------------------------- ---------- ------------- ----- ------------- -------
  Sex (male)                        5890       44.8%         447   47.1%         0.188
  Age (year)                        13137      54.8 ± 9.4    950   55.0 ± 9.5    0.462
  BMI (kg/m^2^)                     10578      23.2 ± 3.4    752   23.1 ± 3.5    0.809
  Systolic blood pressure (mmHg)    10514      128 ± 20.2    747   128 ± 19.1    0.528
  Diastolic blood pressure (mmHg)   10513      78.2 ± 12.3   747   77.9 ± 11.7   0.441
  Triglyceride (mg/dl)              10861      128 ± 96.5    792   130 ± 94.0    0.585
  Total cholesterol (mg/dl)         9947       211 ± 34.7    749   211 ± 36.0    0.821
  nonHDL-C (mg/dl)                  9946       148 ± 35.1    749   149 ± 36.1    0.781
  HDL-C (mg/dl)                     10863      62.7 ± 16.3   792   62.3 ± 15.8   0.458
  Hemoglobin A1C (%)                8057       5.55 ± 0.73   581   5.61 ± 0.74   0.055
  eGFR (mL/min/1.73 m^2^)           10509      78.8 ± 15.1   774   78.3 ± 14.9   0.374
  Alcohol drinking                                                               
      0 g/d                         5912       45.8%         433   46.6%         
      0.1--22.9 g/d                 4224       32.7%         305   32.8%         
      23--45.9 g/d                  1412       10.9%         101   10.9%         0.870
      46.0+ g/d                     1359       10.5%         90    9.7%          
  Smoking                           2471       18.8%         171   18.0%         0.574
  Regular physical activity         3830       29.2%         289   30.5%         0.417

  Genotype                          rs77035639   *p* value                         
  --------------------------------- ------------ ------------- ----- ------------- -------
  Sex (male)                        6114         44.9%         223   46.2%         0.609
  Age (year)                        13604        54.8 ± 9.4    483   54.5 ± 9.3    0.587
  BMI (kg/m^2^)                     10937        23.2 ± 3.4    393   23.3 ± 3.2    0.562
  Systolic blood pressure (mmHg)    10874        128 ± 20.1    387   128 ± 20.4    0.605
  Diastolic blood pressure (mmHg)   10873        78.2 ± 12.2   387   77.6 ± 12.3   0.318
  Triglyceride (mg/dl)              11246        128 ± 96.3    407   129 ± 96.0    0.868
  Total cholesterol (mg/dl)         10326        211 ± 34.7    370   211 ± 36.1    0.966
  nonHDL-C (mg/dl)                  10325        148 ± 35.1    370   149 ± 36.5    0.879
  HDL-C (mg/dl)                     11248        62.7 ± 16.3   407   62.5 ± 15.6   0.795
  Hemoglobin A1C (%)                8347         5.55 ± 0.73   291   5.63 ± 0.91   0.171
  eGFR (mL/min/1.73 m^2^)           10899        78.7 ± 15.1   384   78.2 ± 13.8   0.527
  Alcohol drinking                                                                 
      0 g/d                         6136         45.9%         209   44.5%         
      0.1--22.9 g/d                 4376         32.7%         153   32.6%         
      23--45.9 g/d                  1458         10.9%         55    11.7%         0.856
      46.0+ g/d                     1396         10.4%         53    11.3%         
  Smoking                           2548         18.7%         94    19.5%         0.682
  Regular physical activity         3985         29.3%         134   27.7%         0.475

  Genotype                          rs3815524   *p* value                          
  --------------------------------- ----------- ------------- ------ ------------- -------
  Sex (male)                        5613        45.0%         724    44.6%         0.750
  Age (year)                        12464       54.8 ± 9.4    1623   54.7 ± 9.4    0.816
  BMI (kg/m^2^)                     10010       23.2 ± 3.4    1320   23.2 ± 3.3    0.950
  Systolic blood pressure (mmHg)    9949        128 ± 20.1    1312   128 ± 20.1    0.868
  Diastolic blood pressure (mmHg)   9948        78.3 ± 12.2   1312   77.9 ± 12.1   0.374
  Triglyceride (mg/dl)              10288       128 ± 96.3    1365   130 ± 96.3    0.447
  Total cholesterol (mg/dl)         9426        211 ± 34.8    1270   212 ± 34.2    0.703
  nonHDL-C (mg/dl)                  9425        148 ± 35.2    1270   149 ± 35.0    0.382
  HDL-C (mg/dl)                     10289       62.7 ± 16.3   1366   62.3 ± 15.8   0.372
  Hemoglobin A1C (%)                7659        5.56 ± 0.74   979    5.55 ± 0.66   0.684
  eGFR (mL/min/1.73 m^2^)           9966        78.8 ± 15.2   1317   78.3 ± 14.1   0.237
  Alcohol drinking                                                                 
      0 g/d                         5615        45.8%         730    46.1%         
      0.1--22.9 g/d                 4007        32.7%         522    32.9%         
      23--45.9 g/d                  1336        10.9%         177    11.2%         0.848
      46.0+ g/d                     1293        10.6%         156    9.8%          
  Smoking                           2345        18.8%         297    18.3%         0.635
  Regular physical activity         3655        29.4%         464    28.6%         0.542

  Genotype                          rs75380157   *p* value                          
  --------------------------------- ------------ ------------- ------ ------------- -------
  Sex (male)                        5843         45.5%         494    44.5%         0.777
  Age (year)                        12978        54.8 ± 9.4    1109   54.6 ± 9.4    0.629
  BMI (kg/m^2^)                     10439        23.2 ± 3.4    891    23.0 ± 3.2    0.280
  Systolic blood pressure (mmHg)    10377        128 ± 20.1    884    128 ± 20.3    0.845
  Diastolic blood pressure (mmHg)   10376        78.3 ± 12.2   884    77.9 ± 12.3   0.367
  Triglyceride (mg/dl)              10734        128 ± 96.1    919    129 ± 98.9    0.663
  Total cholesterol (mg/dl)         9829         211 ± 34.8    867    211 ± 34.4    0.888
  nonHDL-C (mg/dl)                  9829         148 ± 35.2    867    149 ± 34.7    0.930
  HDL-C (mg/dl)                     10735        62.7 ± 16.3   920    62.5 ± 15.6   0.723
  Hemoglobin A1C (%)                7954         5.56 ± 0.74   684    5.56 ± 0.71   0.794
  eGFR (mL/min/1.73 m^2^)           10393        78.8 ± 15.2   890    78.1 ± 14.0   0.190
  Alcohol drinking                                                                  
      0 g/d                         5841         45.8%         504    46.5%         
      0.1--22.9 g/d                 4169         32.7%         360    33.2%         
      23--45.9 g/d                  1393         10.9%         120    11.1%         0.637
      46.0+ g/d                     1348         10.6%         101    9.3%          
  Smoking                           2424         18.7%         218    19.7%         0.424
  Regular physical activity         3801         29.3%         318    28.7%         0.679

  Genotype                          rs74603859   *p* value                         
  --------------------------------- ------------ ------------- ----- ------------- -----------
  Sex (male)                        6044         45.1%         293   43.0%         0.287
  Age (year)                        13405        54.8 ± 9.4    682   54.8 ± 9.2    0.889
  BMI (kg/m^2^)                     10778        23.1 ± 3.4    552   23.6 ± 3.5    **0.001**
  Systolic blood pressure (mmHg)    10711        128 ± 20.1    550   130 ± 20.6    **0.020**
  Diastolic blood pressure (mmHg)   10710        78.2 ± 12.2   550   79.0 ± 12.1   0.137
  Triglyceride (mg/dl)              11082        128 ± 95.0    571   133 ± 118     0.192
  Total cholesterol (mg/dl)         10183        211 ± 34.8    513   212 ± 34.4    0.871
  nonHDL-C (mg/dl)                  10182        148 ± 35.2    513   150 ± 34.8    0.393
  HDL-C (mg/dl)                     11084        62.7 ± 16.3   571   61.9 ± 15.9   0.213
  Hemoglobin A1C (%)                8235         5.55 ± 0.72   403   5.59 ± 0.94   0.277
  eGFR (mL/min/1.73 m^2^)           10732        78.7 ± 15.1   551   79.4 ± 14.7   0.302
  Alcohol drinking                                                                 
      0 g/d                         6033         45.8%         312   46.7%         
      0.1--22.9 g/d                 4325         32.8%         204   30.5%         
      23--45.9 g/d                  1432         10.9%         81    12.1%         0.558
      46.0+ g/d                     1378         10.5%         71    10.6%         
  Smoking                           2523         18.8%         119   17.5%         0.392
  Regular physical activity         3905         29.2%         214   31.4%         0.210

  Genotype                          rs147565266   *p* value                        
  --------------------------------- ------------- ------------- ---- ------------- -------
  Sex (male)                        6305          45.0%         32   50.8%         0.376
  Age (year)                        14024         54.8 ± 9.4    63   56.0 ± 8.3    0.312
  BMI (kg/m^2^)                     11277         23.2 ± 3.4    53   23.3 ± 3.2    0.739
  Systolic blood pressure (mmHg)    11209         128 ± 20.1    52   133 ± 26.2    0.189
  Diastolic blood pressure (mmHg)   11208         78.2 ± 12.2   52   79.6 ± 14.6   0.501
  Triglyceride (mg/dl)              11599         128 ± 95.9    54   151 ± 161     0.293
  Total cholesterol (mg/dl)         10644         211 ± 34.7    52   215 ± 36.6    0.446
  nonHDL-C (mg/dl)                  10643         148 ± 35.1    52   152 ± 39.1    0.488
  HDL-C (mg/dl)                     11601         62.7 ± 16.2   54   62.9 ± 21.2   0.950
  Hemoglobin A1C (%)                8592          5.56 ± 0.73   46   5.63 ± 0.84   0.520
  eGFR (mL/min/1.73 m^2^)           11230         78.7 ± 15.1   53   80.2 ± 14.2   0.482
  Alcohol drinking                                                                 
      0 g/d                         6318          45.9%         27   43.5%         
      0.1--22.9 g/d                 4513          32.8%         16   25.8%         
      23--45.9 g/d                  1505          10.9%         8    12.9%         0.226
      46.0+ g/d                     1438          10.4%         11   17.7%         
  Smoking                           2632          18.8%         10   15.9%         0.631
  Regular physical activity         4105          29.3%         14   22.2%         0.268

Homo, homozygote; Hetero, heterozygote.

###### Genotype and allele distributions in obesity, ischemic heart disease, hypertension, dyslipidemia, and diabetes.

  SNPs          Genotype     Obesity           Ischemic heart disease           Hypertension           Dyslipidemia           Diabetes                                      
  ------------- ------------ --------- ------- ------------------------ ------- -------------- ------- -------------- ------- ---------- ------ ------ ------- ------ ----- -----------
  rs753152      Major Homo   7823      2755    0.729                    12006   374            0.774   6624           3889    0.432      6396   3676   0.846   7496   561   **0.030**
  74.0%         26.0%        97.0%     3.0%    63.0%                    37.0%   63.5%          36.5%   93.0%          7.0%                                                  
                                                                                                                                                                            
  Hetero+       561          191       883     29                       482     265            476     278            526     55                                            
  Minor Homo    74.6%        25.4%     96.8%   3.2%                     64.5%   35.5%          63.1%   36.9%          90.5%   9.5%                                          
                                                                                                                                                                            
  rs77035639    Major Homo   8097      2840    0.643                    12447   388            0.678   6864           4009    0.832      6642   3810   0.414   7758   589   0.163
  74.0%         26.0%        97.0%     3.0%    63.1%                    36.9%   63.5%          36.5%   92.9%          7.1%                                                  
                                                                                                                                                                            
  Hetero+       287          106       442     15                       242     145            230     144            264     27                                            
  Minor Homo    73.0%        27.0%     96.7%   3.3%                     62.5%   37.5%          61.5%   38.5%          90.7%   9.3%                                          
                                                                                                                                                                            
  rs3815524     Major Homo   7423      2587    0.301                    11399   351            0.388   6275           3673    0.878      6067   3473   0.498   7105   554   0.323
  74.2%         25.8%        97.0%     3.0%    63.1%                    36.9%   63.6%          36.4%   92.8%          7.2%                                                  
                                                                                                                                                                            
  Hetero+       961          359       1490    52                       831     481            805     481            917     62                                            
  Minor Homo    72.8%        27.2%     96.6%   3.4%                     63.3%   36.7%          62.6%   37.4%          93.7%   6.3%                                          
                                                                                                                                                                            
  rs75380157    Major Homo   7718      2721    0.632                    11878   366            0.349   6541           3835    0.611      6316   3634   1.000   7381   573   0.395
  73.9%         26.1%        97.0%     3.0%    63.0%                    37.0%   63.5%          36.5%   92.8%          7.2%                                                  
                                                                                                                                                                            
  Hetero+       666          225       1011    37                       565     319            556     320            641     43                                            
  Minor Homo    74.7%        25.3%     96.5%   3.5%                     63.9%   36.1%          63.5%   36.5%          93.7%   6.3%                                          
                                                                                                                                                                            
  rs574603859   Major Homo   8001      2777    **0.012**                12255   385            0.803   6778           3932    0.085      6550   3759   0.575   7648   587   0.921
  74.2%         25.8%        97.0%     3.0%    63.3%                    36.7%   63.5%          36.5%   92.9%          7.1%                                                  
                                                                                                                                                                            
  Hetero+       383          169       634     18                       328     222            322     195            374     29                                            
  Minor Homo    69.4%        30.6%     97.2%   2.8%                     59.6%   40.4%          62.3%   37.7%          92.8%   7.2%                                          
                                                                                                                                                                            
  rs147565266   Major Homo   8345      2932    1.000                    12833   402            1.000   7079           4129    0.111      6841   3933   0.570   7981   611   0.378
  74.0%         26.0%        97.0%     3.0%    63.2%                    36.8%   63.5%          36.5%   92.9%          7.1%                                                  
                                                                                                                                                                            
  Hetero+       39           14        56      1                        27      25             31      21             41      5                                             
  Minor Homo    73.6%        26.4%     98.2%   1.8%                     51.9%   48.1%          59.6%   40.4%          89.1%   10.9%                                         

Homo, homozygote; Hetero, heterozygote.

To determine the relationship of the SNPs with stroke in consideration of environmental factors, a logistic regression analysis adjusted for age, sex, research area, alcohol intake, current smoking, regular physical activity, obesity, hypertension, diabetes, dyslipidemia, and ischemic heart disease was performed. For the logistic regression analysis, the major homozygous genotypes were used as the reference group and the heterozygous and minor homozygous genotypes were used as the exposed group in the dominant model. **[Table 4](#T4){ref-type="table"}** shows model I adjusted for basic characteristics (age, sex, research area), model II adjusted for lifestyle, and model III adjusted for anamnesis. *RAMP2* SNP rs753152 was associated with a significantly higher OR in model I (OR, 1.773; 95% CI, 1.194--2.634). The *CLR* SNPs were associated with a significantly higher OR in model I (OR, 1.448--3.735) in participants with stroke, excluding rs574603859. SNP rs574603859 had a lower OR in model I (OR, 0.238; 95% CI, 0.076--0.745) between major homozygotes and the others. The model II results were similar to those for model I. In model III, rs574603859 showed no significant OR. The lack of statistical significance when adjusting for anamnesis indicated that rs574603859 has no strong effect on the risk of stroke.

###### Associations between the *RAMP2* and *CLR* gene variants and stroke.

  SNPs          Model I   Model II       Model III                                                             
  ------------- --------- -------------- ----------- ------- -------------- ----------- ------- -------------- -----------
  rs753152      1.773     1.194--2.634   **0.005**   1.784   1.200--2.652   **0.004**   1.767   1.059--2.947   **0.029**
  rs77035639    2.015     1.199--3.385   **0.008**   2.084   1.239--3.506   **0.006**   2.25    1.177--4.302   **0.014**
  rs3815524     1.448     1.023--2.051   **0.037**   1.482   1.046--2.099   *0.027*     1.908   1.259--2.891   **0.002**
  rs75380157    1.845     1.270--2.683   **0.001**   1.877   1.290--2.731   **0.001**   2.115   1.338--3.342   **0.001**
  rs574603859   0.238     0.076--0.745   **0.014**   0.245   0.078--0.768   **0.016**   0.276   0.068--1.126   0.073
  rs147565266   3.735     1.325--10.52   **0.013**   3.997   1.412--11.31   **0.009**   5.316   1.775--15.92   **0.002**

Model I: adjusted for age, sex, research area

Model II: adjusted for age, sex, research area, alcohol intake, current smoking, regular physical activity, obesity

Model III: adjusted for age, sex, research area, alcohol intake, current smoking, regular physical activity, obesity, hypertension, diabetes, dyslipidemia, ischemic heart disease

Discussion
==========

There is considerable evidence to suggest that the pathogenesis of stroke is affected by not only genetic factors, but also environment interactions^[@bib9])^. Previous studies showed that a history of hypertension, dyslipidemia, diabetes, physical inactivity, diet, waist-to-hip ratio, current smoking, cardiac causes, and alcohol consumption were associated with risk of stroke^[@bib32],\ [@bib33])^. There was a J-shaped association between high amounts of alcohol and increased risk of both ischemic and hemorrhagic stroke^[@bib34])^. Therefore, we defined age, sex, research area, alcohol consumption status, current smoking, regular physical activity, obesity, hypertension, diabetes, dyslipidemia, and ischemic heart disease as independent variables in the logistic regression analyses. To the best of our knowledge, this is the first study to investigate the relationships between *RAMP2* and *CLR* and stroke in the light of gene-environment interactions in humans.

The pathogenesis of stroke is very complex and is associated closely with vascular dysfunction and disruption. Indeed, similar to chronic obstructive pulmonary disease, systemic inflammation and oxidative stress might play important roles in increasing the risk of stroke by promoting vascular dysfunction and platelet hyperactivity^[@bib35])^. A review study showed that ADM has strong anti-oxidation and anti-inflammation activities^[@bib14])^. Moreover, ADM acts via CLR/RAMP2 to prevent brain injury in both acute and chronic cerebral ischemia^[@bib36])^, and exerts crucial vasoprotective effects following vascular injury^[@bib37])^. The vascular ADM-CLR/RAMP2 system is critical in the regulation of vascular integrity, including the maintenance of vascular structure, and the regulation of angiogenesis and vasoprotection against vascular injury^[@bib14],\ [@bib19])^. Studying the ADM-CLR/RAMP2 system should reveal the mechanisms underlying the functional integrity of the vascular system, and could serve as the basis for novel approaches to therapy and preventive medicine.

RAMP expression is modulated by various agents in cell culture and in animal models of human disease^[@bib38])^. For example, marked changes induced in the cardiovascular and renal systems provided evidence of an important role for dynamic RAMP regulation in those systems. Studies suggest that regulation of RAMPs might modulate the pathophysiology of conditions linked to RAMP-interacting G protein-coupled receptors. For example, human SNP studies described the relationship between *CLR* and essential hypertension and primary angle closure glaucoma^[@bib39],\ [@bib40])^. Polymorphisms in the *ADM* gene have also been reported to have a possible association with essential hypertension, dysglycemia, and adrenomedullin levels^[@bib41]--[@bib45])^. Genetic variants of the ADM-CLR/RAMP2 system might affect vascular homeostasis and cerebrovascular/cardiovascular disease. Several studies have revealed interactions of SNPs with stroke^[@bib46]--[@bib49])^. In these studies, the functional genetic polymorphisms were located in the promoters, which could cause differences in the plasma levels of the encoded target protein; were located in coding exons, leading to amino acid changes; or were located in an intron. Although we demonstrated that an intronlocated SNP is not functional, it could have other effects, such as influencing splicing or regulatory processes; for example, the binding of transcription factors to the gene. Furthermore, as a tag SNP, the polymorphism might be representative of many other variants, which could regulate the function of the receptor.

The limitations of our study include its cross-sectional design. However, case-control studies can be used to assess previously identified candidate regions and to determine target selections more precisely. In general, strokes can be divided into three subtypes: ischemic, lacunar, and hemorrhagic. In this study, we did not investigate the subtypes of stroke because we used a self-administered questionnaire to judge anamnesis. By contrast, a previous study reported that stroke and myocardial infarct seem sensitive enough to use self-administered questionnaire for judgment at baseline in Japanese cohort studies^[@bib50])^. In a future (follow-up) survey, we plan to assess the participants by looking up the actual medical records; therefore, we expect these additional data will lead to further detailed analysis of genetic variants of *ADM* receptor genes in accordance with the stroke subtypes and cardiovascular disease. In addition, we only assessed Japanese participants in the present study, and further studies in other ethnic groups are needed to validate our findings.

Conclusions
===========

In conclusion, the association of the *RAMP2* and *CLR* genes with stroke in a Japanese cohort implicates these genes in the pathogenesis of stroke, although further investigation is required to confirm their associations. It will be interesting to determine whether the polymorphisms of *RAMP2* and *CLR* are responsible for functional changes, and to reveal the underlying mechanism, given the potentially important role that *ADM* receptor genes play in stroke and/or vascular fragility.
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